Jerry Mclaughlin PhD

AgeneBio is developing drugs to treat the pre dementia stage of Alzheimers disease, and other neurological and psychiatric conditions. The company announced encouraging mid stage results for its lead therapeutic, which works by quieting hyperactivity in the hippocampus portion of the brain, which plays a critical role in the formation of memory. We spoke to Jerry McLaughlin, CEO of AgeneBio about the company’s efforts, why this approach holds promise in delaying the onset of dementia in Alzheimers patients, and whether this approach may have implications for other neurological and psychiatric.